You are here: Industry Insights > Liver cancer

News List

Exelixis enters crowded liver cancer field with Cabometyx, taking on Bayer, BMS and Merck fiercepharma
January 17, 2019
Exelixis’ fast-growing tyrosine kinase inhibitor Cabometyx just added another FDA approval. It can now treat liver cancer patients if Bayer’s Nexavar is no longer helpful, putting it in a field that’s already crowded with Bayer’s Stivarga and some checkpo
Exelixis’ Cabometyx approved in second-line liver cancer in US pharmaphorum
January 16, 2019
Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.
NICE recommends Lenvima for advanced liver cancer pharmatimes
December 24, 2018
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima (lenvatinib), a potentially life-extending treatment for advanced hepatocellular carcinoma (HCC) in adults
AZ begins liver cancer immunotherapy tie-up with AVEO pharmaphorum
December 14, 2018
AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.
Risk Factors Identified for Late Recurrence of Liver Cancer drugs
December 14, 2018
Late recurrence after hepatocellular carcinoma (HCC) resection is associated with sex, cirrhosis, and several aggressive tumor characteristics of the initial HCC ......
Merck gets FDA okay for Keytruda as liver cancer therapy pharmaphorum
December 12, 2018
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its rivalry with Bristol-Myers Squibb.....
Nature Review: Market Forecast of the Global Liver Cancer Drug Market Weiyi
December 12, 2018
The liver cancer drug market size is expected to grow from USD870 million (2017) to nearly USD4 billion (2027), which will benefit from the marketing of other 8 high-priced biologics and the extensive promotion of nivolumab as a first-line therapy.
Important pipelines in development of the Liver Cancer Drug Weiyi
December 11, 2018
The angiogenesis inhibitors and immune checkpoint inhibitors are the directions of main liver cancer drugs in development, and the drug combinations are also in development.
Nature Review: Current Situation of the Global Liver Cancer Drug Market Weiyi
December 11, 2018
Liver cancer has become one of the tumors with high fatality rate among cancers in the U.S., and is mainly treated through systemic palliative care in the advanced stage.
Bayer’s Stivarga wins NICE backing for advanced liver cancer pharmatimes
November 29, 2018
Bayer’s Stivarga has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE) following a rapid review of guidance published earlier in the year which rejected the drug.

Previous page 1 2 3 4 5 Next page